Advances in Our Understanding of ＂Resistance＂ to Antiplatelet Agents for Prevention of Ischemic Stroke

Cheng, L. (2011). The role of exchange protein directly activated by cyclic AMP 2-deficiency in ischemic stroke [master's thesis, The University of Hong Kong]. Airiti Library. https://www.airitilibrary.com/Article/Detail?DocID=U0029-1812201200020145
Asadi, H., Yan, B., Dowling, R., Wong, S., & Mitchell, P. (2014). Advances in Medical Revascularisation Treatments in Acute Ischemic Stroke. Thrombosis, (2014), e1-14. https://doi.org/10.1155/2014/714218
陳志昊、湯頌君、鄭建興（2020）。Dual Antiplatelet Therapy in Acute Stroke: A New Hope?。台灣中風醫誌，2(3)，223-229。https://doi.org/10.6318/FJS.202009_2(3).0004
Shiau, Y. F. (2009). Secondary Prevention of Stroke and Death by Antiplatelet Therapies in Patients with Ischemic Stroke or Transient Ischemic Attack [master's thesis, Taipei Medical University]. Airiti Library. https://doi.org/10.6831/TMU.2009.00079
Po, H. L., Lin, Y. J., & Hseuh, I. H. (2009). The Prescribing Patterns of Antithrombotic Agents for Prevention of Recurrent Ischemic Stroke. Acta Neurologica Taiwanica, 18(2), 98-103. https://doi.org/10.29819/ANT.200906.0004